Transforming clinical genetic data into multi-OMICs insights

Mississauga – GenomeArc, a pioneering force in genomic technology, is proud to announce the Early Access Program for Version 2 of its Clinical Genetics Multi-Omics Platform, GenomeArc Horizon. This advanced platform promises to transform how clinical geneticists and researchers work by delivering multi-omics insights with unparalleled speed and accuracy.

Building on the success of its first version, the new release combines cutting-edge AI called Horizon Intelligence with powerful genomics and multi-OMICs integration. The Early Access Program gives participants exclusive access to these capabilities before the full release, offering a chance to gain insights into their data and try the platform for free.

The biotech company founder, Dr. Mohammed Uddin, announced that Horizon V2 can “classify pathogenicity of over 5 million variants (SNVs, Indels, and SVs) in just 10 minutes for diagnosis support using phased VCFs from Oxford Nanopore Technologies or PacBio.” The new version has taken that a step further and integrated different multi-OMICs with the analysis.

Why Join the Early Access Program?

For a limited time, GenomeArc will provide free access to Horizon V2 before the official launch. The early access program will be open for a select number of scientists and clinicians from October 17th to October 31st . It will have all the features of Horizon version 2 and users can try it on their own data.

The second version will include: ACMG guided diagnosis support, Carrier Screening, Secondary Findings, and the new Horizon Intelligence and Multi-OMICs data integration.

How to Apply

Spaces for the Early Access Program are limited. To apply for Version 2 and discover how this platform can transform your analysis, visit GenomeArc’s early access page (GenomeArc Horizon) today and secure your spot.

GenomeArc Inc.

Email: info@genomearc.com